1040 Spring Street
Silver Spring, MD 20910
301 608 9292
Full Time Employees: 985
|Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.||Founder, Chairman & CEO||3.51M||5.08M||1955|
|Mr. Michael I. Benkowitz||Pres & COO||1.96M||17.34M||1972|
|Mr. James C. Edgemond||CFO & Treasurer||1.42M||N/A||1968|
|Mr. Paul A. Mahon J.D.||Exec. VP, Gen. Counsel & Corp. Sec.||1.67M||12.39M||1964|
|Mr. Dewey Steadman C.F.A.||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Holly Hobson||Associate VP of HR||N/A||N/A||N/A|
|Kevin T. Gray||Sr. VP of Strategic Operations & Logistics||N/A||N/A||N/A|
|Mr. Patrick Poisson||Exec. VP of Technical Operations||N/A||N/A||1968|
|Mr. Gil Golden||Sr. VP & Chief Medical Officer||N/A||N/A||N/A|
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation’s ISS Governance QualityScore as of March 1, 2023 is 4. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 3; Compensation: 5.